European antitrust regulators are looking into Aspen Pharmacare's price hikes on a handful of cancer meds.
Rocked by a corruption scandal in Korea, Novartis is working to strengthen and simplify its global ethics and compliance approach.
Three biosimilars for rheumatoid arthritis (RA) were approved by the FDA last year, but the regulatory pathway in the US is still considered a new frontier,…
Johnson & Johnson has agreed to pay about $400,000 to settle a suit in Oregon claiming the company acted improperly in recalling lots of faulty Motrin.
Reeling from multiple court defeats in litigation linking its talc products to ovarian cancer, Johnson & Johnson is taking its arguments to appeals court.
Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, triggering a 20% run-up in its share price.
Johnson & Johnson is facing a fresh round of marketing scrutiny, with federal and state investigators probing the promotion of top arthritis and hep C meds.
Gilead Sciences could soon find itself facing yet another challenge, this time from the U.S. government.
Johnson & Johnson took a damaging hit late Thursday as a St. Louis jury awarded the largest verdict to date in the ongoing saga.
Pfizer thought it had escaped the prospect of paying royalties on its lung cancer drug Xalkori, but an appeals court has resurrected NYU's legal claims.
The first trial over blockbuster Xarelto’s bleeding risks has swung in Bayer and Johnson & Johnson’s favor.